Target intelligence / Profile preview

Ceroid-lipofuscinosis, neuronal 8 transmembrane ER and ERGIC protein (CLN8)

Target
CLN8
Molecular classification
Transmembrane protein, ER cargo receptor, Lysosomal trafficking protein, Other (TLC-domain containing protein)
01

Overview

Ceroid-lipofuscinosis, neuronal 8 transmembrane ER and ERGIC protein (CLN8) is a polytopic transmembrane protein predominantly localized to the endoplasmic reticulum (ER) and shuttling between the ER and ER-Golgi intermediate compartment (ERGIC)[1][2][3][4]. CLN8 plays a central role in the trafficking of soluble lysosomal enzymes from the ER to the Golgi apparatus, acting as a cargo receptor essential for proper lysosome biogenesis and function[2][3][4]. It interacts with the protein CLN6 to form the EGRESS complex, which recruits lysosomal proteins and ensures their correct export from the ER[1][3][4]. In addition to its trafficking function, CLN8 is involved in cellular lipid metabolism and may act as a sphingolipid sensor, thereby modulating ceramide-dependent signaling[1]. Mutations in CLN8 cause a neurodegenerative lysosomal storage disorder known as neuronal ceroid lipofuscinosis 8 (NCL8 or Batten disease), commonly presenting as childhood-onset epilepsy and progressive cognitive decline[1][2][3][4]. Loss of CLN8 function leads to impaired delivery of lysosomal enzymes, lysosomal enzyme deficiency, and subsequent neurodegeneration due to defective lysosome biogenesis[1][2][4]. No small-molecule drugs directly targeting CLN8 are currently known.

Other names
Protein CLN8C8orf61FLJ39417TLCD6EPMRceroid-lipofuscinosis neuronal 8transmembrane ER and ERGIC proteinCLN8 transmembrane ER and ERGIC protein
02

Biological functions

Lysosomal enzyme traffickingLysosome biogenesisLipid metabolism (including ceramide and sphingolipids)Regulation of neuronal proliferation and survival
03

Disease associations

Neurodegenerative disease (neuronal ceroid lipofuscinoses, Batten disease)Other (progressive epilepsy with mental retardation)
04

Safety considerations

Targeting CLN8 may disrupt lysosomal enzyme traffickingPotential for neurodegeneration, lysosomal storage disease phenotypes if disrupted
05

Biomarkers

Mutations in CLN8 are biomarkers for neuronal ceroid lipofuscinosis 8/Batten diseaseAltered levels of sphingolipids and phospholipids in brain tissue in affected patients

Beyond the preview

Go deeper on Ceroid-lipofuscinosis, neuronal 8 transmembrane ER and ERGIC protein (CLN8).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ceroid-lipofuscinosis, neuronal 8 transmembrane ER and ERGIC protein (CLN8).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call